Background: There are no data regarding the management of advanced soft-tissue sarcoma (STS) in elderly patients.Patients and methods: We retrospectively reviewed the charts of patients >= 75 years old diagnosed with metastatic or unresectable STS between 1991 and 2011 in 11 French and American centers.Results: The study included 361 patients. Of these, 223 patients (62%) received systemic therapy, whereas 123 patients (34%) were managed with best supportive care (BSC) only. Patients who received BSC were more likely to be >= 80 years, with performance status (PS) >= 2, Charlson comorbidity score >= 10, and metastatic disease. The median progression-free survival of patients treated with systemic therapy was 4 months (95% CI: 2.9-5.1). Thirty-six patients (16%) stopped chemotherapy because of toxicity. Median overall survival (OS) of patients managed with specific therapy was 10.9 months (95% CI: 8.3-13.5) versus 5.3 months (95% CI: 3.6-7.1) for patients managed with BSC (P = 0.001). On multivariate analysis, age >= 80 years, PS >= 2, and number of metastatic sites were the only independent factors associated with OS.Conclusion: A high proportion of elderly patients with advanced STS were denied chemotherapy. Further efforts are needed to define better the optimal care for fit and unfit elderly patients with STS.
Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival
Zanardi, E.;
2013-01-01
Abstract
Background: There are no data regarding the management of advanced soft-tissue sarcoma (STS) in elderly patients.Patients and methods: We retrospectively reviewed the charts of patients >= 75 years old diagnosed with metastatic or unresectable STS between 1991 and 2011 in 11 French and American centers.Results: The study included 361 patients. Of these, 223 patients (62%) received systemic therapy, whereas 123 patients (34%) were managed with best supportive care (BSC) only. Patients who received BSC were more likely to be >= 80 years, with performance status (PS) >= 2, Charlson comorbidity score >= 10, and metastatic disease. The median progression-free survival of patients treated with systemic therapy was 4 months (95% CI: 2.9-5.1). Thirty-six patients (16%) stopped chemotherapy because of toxicity. Median overall survival (OS) of patients managed with specific therapy was 10.9 months (95% CI: 8.3-13.5) versus 5.3 months (95% CI: 3.6-7.1) for patients managed with BSC (P = 0.001). On multivariate analysis, age >= 80 years, PS >= 2, and number of metastatic sites were the only independent factors associated with OS.Conclusion: A high proportion of elderly patients with advanced STS were denied chemotherapy. Further efforts are needed to define better the optimal care for fit and unfit elderly patients with STS.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
